Ongoing clinical trials in AML involving BH3 mimetics
| Clinicaltrials.gov identifier . | Disease state(s) . | Clinical trial . | Target . | Phase . |
|---|---|---|---|---|
| NCT02993523 | AML (elderly; treatment naive) | Azacitidine + venetoclax (vs azacitidine + placebo) | BCL-2 | 3 |
| NCT03069352 | AML (elderly; treatment naive) | Low-dose cytarabine + venetoclax (vs low-dose cytarabine + placebo) | BCL-2 | 3 |
| NCT02670044 | R/R AML | Cobimetinib (MEK inhibitor) or idasanutlin (HDM2 inhibitor) + venetoclax | BCL-2 | 1B/2 |
| NCT03214562 | R/R and naive AML | FLAG-IDA/venetoclax in patients with newly diagnosed or R/R AML | BCL-2 | 1B/2 |
| NCT02920541 | R/R and elderly treatment naive | Dose-escalation study of oral administration of S055746 in patients with AML or MDS | BCL-2 | 1 |
| ACTRN12616000445471 | Elderly newly diagnosed | Cytarabine, idarubicin with venetoclax | BCL-2 | 1/2 |
| NCT03194932 | R/R (2-20 years old) | Venetoclax in combination with chemotherapy in pediatric patients with R/R AML or acute leukemia of ambiguous lineage | BCL-2 | 1/2 |
| CT03082209 | Solid tumor, AML or DLBCL (all R/R) | TRAIL receptor agonist ABBV-621 in subjects with previously treated solid tumors and hematologic malignancies (segment II: ABBV-621 + venetoclax) | BCL-2 | 1 |
| NCT02391480 | Cancers, R/R AML, MM, NHL | Safety and pharmacokinetics of ABBV-075 in subjects with cancer (expansion cohort of ABBV-075 and venetoclax) | BCL-2 | 1 |
| NCT03537482 | R/R hematologic malignancies | A phase I study of safety, tolerability, pharmacokinetic and pharmacodynamics property of orally administered APG-2575 in patients with hematologic malignancies | BCL-2 | 1 |
| NCT02979366 | R/R, secondary to MDS and elderly treatment naive | S64315, a Mcl-1 inhibitor, administered intravenously in patients with AML or MDS | MCL-1 | 1 |
| NCT02675452 | MM, R/R AML | AMG 176 first in human trial in subjects with R/R MM and subjects with R/R AML | MCL-1 | 1 |
| NCT03218683 | R/R hematologic malignancies | AZD5991 in R/R hematologic malignancies | MCL-1 | 1 |
| Clinicaltrials.gov identifier . | Disease state(s) . | Clinical trial . | Target . | Phase . |
|---|---|---|---|---|
| NCT02993523 | AML (elderly; treatment naive) | Azacitidine + venetoclax (vs azacitidine + placebo) | BCL-2 | 3 |
| NCT03069352 | AML (elderly; treatment naive) | Low-dose cytarabine + venetoclax (vs low-dose cytarabine + placebo) | BCL-2 | 3 |
| NCT02670044 | R/R AML | Cobimetinib (MEK inhibitor) or idasanutlin (HDM2 inhibitor) + venetoclax | BCL-2 | 1B/2 |
| NCT03214562 | R/R and naive AML | FLAG-IDA/venetoclax in patients with newly diagnosed or R/R AML | BCL-2 | 1B/2 |
| NCT02920541 | R/R and elderly treatment naive | Dose-escalation study of oral administration of S055746 in patients with AML or MDS | BCL-2 | 1 |
| ACTRN12616000445471 | Elderly newly diagnosed | Cytarabine, idarubicin with venetoclax | BCL-2 | 1/2 |
| NCT03194932 | R/R (2-20 years old) | Venetoclax in combination with chemotherapy in pediatric patients with R/R AML or acute leukemia of ambiguous lineage | BCL-2 | 1/2 |
| CT03082209 | Solid tumor, AML or DLBCL (all R/R) | TRAIL receptor agonist ABBV-621 in subjects with previously treated solid tumors and hematologic malignancies (segment II: ABBV-621 + venetoclax) | BCL-2 | 1 |
| NCT02391480 | Cancers, R/R AML, MM, NHL | Safety and pharmacokinetics of ABBV-075 in subjects with cancer (expansion cohort of ABBV-075 and venetoclax) | BCL-2 | 1 |
| NCT03537482 | R/R hematologic malignancies | A phase I study of safety, tolerability, pharmacokinetic and pharmacodynamics property of orally administered APG-2575 in patients with hematologic malignancies | BCL-2 | 1 |
| NCT02979366 | R/R, secondary to MDS and elderly treatment naive | S64315, a Mcl-1 inhibitor, administered intravenously in patients with AML or MDS | MCL-1 | 1 |
| NCT02675452 | MM, R/R AML | AMG 176 first in human trial in subjects with R/R MM and subjects with R/R AML | MCL-1 | 1 |
| NCT03218683 | R/R hematologic malignancies | AZD5991 in R/R hematologic malignancies | MCL-1 | 1 |
DLBCL, diffuse large B-cell lymphoma; HDM2, human double minute 2; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; R/R, relapsed/refractory.